Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elagolix - Abbvie/Neurocrine Biosciences

Drug Profile

Elagolix - Abbvie/Neurocrine Biosciences

Alternative Names: ABT-620; Elagolix sodium; NBI-56418; ORIAHNN; ORILISSA

Latest Information Update: 21 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer AbbVie; Neurocrine Biosciences
  • Class Analgesics; Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Endometriosis; Menorrhagia; Pain
  • Phase III Uterine leiomyoma
  • Phase II Polycystic ovary syndrome
  • Discontinued Benign prostatic hyperplasia; Prostate cancer

Most Recent Events

  • 27 Apr 2021 AbbVie completes a phase III trial for Menorrhagia associated with uterine fibroids in the USA and Puerto Rico (PO) (NCT03886220)
  • 10 Feb 2021 AbbVie completes a phase II trial for Polycystic ovary syndrome in Puerto Rico and USA (PO) (NCT03951077)
  • 16 Nov 2020 AbbVie plans the observational ENDORSE clinical trial for moderate to severe endometriosis-associated Pain in Israel (PO, Tablet) , (NCT04630990)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top